NCT03356353View on ClinicalTrials.gov

Sildenafil for the Prevention of Right Heart Failure Following LVAD Implantation

PHASE3UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 12, 2018

Primary Completion Date

September 30, 2021

Study Completion Date

January 31, 2022

Conditions
End Stage Heart Failure
Interventions
DRUG

Sildenafil Citrate

20 mg tablets

Trial Locations (4)

Unknown

RECRUITING

University of Calgary, Calgary

R2H 2A6

RECRUITING

St. Boniface Hospital, Winnipeg

N6A 5A5

RECRUITING

London Health Sciences Centre, London

K1Y 4W7

RECRUITING

University of Ottawa Heart Institute, Ottawa

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Calgary

OTHER

NCT03356353 - Sildenafil for the Prevention of Right Heart Failure Following LVAD Implantation | Biotech Hunter | Biotech Hunter